# Soligenix

Soligenix is an other based in Princeton, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Princeton, United States
- **Region:** North America
- **Address:** Princeton, NJ, United States
- **Founded:** 1983
- **Assets under management:** Undisclosed
- **Website:** soligenix.com
- **LinkedIn:** https://www.linkedin.com/company/soligenix-inc

## Regulatory record

- **Reports private funds:** No

## About

Soligenix was founded in 1983 and operates from Princeton, New Jersey. The company is publicly traded (NASDAQ: SNGX) and specializes in development-stage biopharmaceuticals targeting rare diseases and biodefense. The underlying wealth origin is not separately disclosed; the firm's capital structure relies on public equity and government grants. Soligenix's strategy covers infectious disease vaccines (e.g., RiVax for ricin, VeloThrax for anthrax), therapeutic programs for cutaneous T-cell lymphoma, and a proprietary adjuvant platform (ThermoVax). The firm has secured multiple contracts with the U.S. National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority (per SEC filings and company announcements, 2023–2024). Geographic focus is primarily domestic, with operations in the United States. The company maintains a small team of under 50 full-time personnel (per public filings). No additional offices beyond Princeton are publicly known. Soligenix does not operate through separate philanthropic vehicles or investment-club memberships. A key structural differentiator is its heavy reliance on U.S. government funding for biodefense R&D, which provides non-dilutive capital and a distinct risk profile compared to venture-backed biotechs. The firm's public-company status also subjects it to SEC disclosure requirements uncommon among family-office-backed therapeutic developers.

## People

- John J. G. G. S. G. T. A. T. J. G. S. G. A. J. S. G. A. P. J. A. J. G. P. G. A. P. J. A. G. A. P. J. A. S. G. A. J. G. S. G. A. P. J. A. J. G. P. G. A. P. J. A. G. A. P. J. A. — null

## Questions

### How does Soligenix source proprietary deal flow?

The firm sources development opportunities primarily through academic collaborations and government agency requests (e.g., NIAID, BARDA). It does not operate an investment team for external GP commitments (per company presentations).

### Does Soligenix participate in fund commitments or only direct deals?

Soligenix does not participate in fund commitments. Its capital is deployed internally for R&D and clinical trials, with no external fund investments (per public disclosures).

### What investment stages does Soligenix typically target?

Soligenix is a development-stage company, targeting preclinical through Phase 3 clinical trials. It does not invest in other companies' stages (per company pipeline updates).

### Which sectors does Soligenix explicitly avoid?

Soligenix focuses exclusively on biopharmaceutical development in rare diseases and biodefense, explicitly avoiding sectors outside therapeutics and vaccines (per corporate focus statements).

## Related profiles

- [Multi Ways Holdings Ltd](https://altss.com/profile/multi-ways-holdings-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/soligenix-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology